Get started

PHARMA

FSD Pharma (HUGE) - accumulation before next move upFSD Pharma looks like it is in accumulation, before a move upwards that could reach as far as the local resistance 'first trouble area' before retracing back down - there would need to be significant upswing in buying volume to go further than that. Indicators - Bollinger Bands looks awfully similar to how they did in July 2018 shortly before accumulation and bull run. RSI shows price currently sitting at support level. 10 Day MA is pretty neutral, no major bullish momentum but not falling under either. This would be a good play if buying in the green box and selling somewhere in the region of the first trouble area.
HLong
by emotionallydetached
Loxo - Bull pennant and upcoming eventsThis is the weekly chart on Loxo Oncology. This biotech focuses on cancer treatments by targeting genetic mutations that create protein chimers that lead to unregulated cellular proliferation. In English, and very simply, imagine a copy machine. When you press 'Copy' you should get one duplicate of the item you want copied. Cells have similar systems where a protein in the cell membrane receives a signal from the outside world telling the cell to divide and make a copy of itself. Now imagine your copy machine crosses circuits with a 'Repeat' button. This will lead to infinite, unchecked copying. In cancer a similar thing occurs. Genetic mutations can cause the growth signalling protein to get joined to other proteins leading to unchecked, infinite cellular proliferation. This is one of the several steps to developing cancer. Loxo has developed and is testing drugs that target these specific mutations. Their leading drug, Lorotrectinib, targets TRK fusion proteins (-tinib as a suffix indicates it inhibits tyrosine kinases) and has shown good efficacy in combating several types of cancer with minimal side effects reported. Notable upcoming events are a data review at an upcoming oncology conference October 19-23, Earnings Report on 11/5/18, and a New Drug Application review PDUFA by the FDA on 11/26/2018. The last date is the most important as Loxo could see Lorotrectinib obtain FDA approval. Other possibilities for the PDUFA are an extension of the review or rejection of the drug. From the research reports I have read so far on Lorotrectinib I am doubtful a rejection/denial will happen. I suspect it will either be approved or the review extended and this will depend upon new data, likely to be presented in October. The chart currently looks bullish to me. There is a clear uptrend long term with us likely in a Wave 2 in Elliot Wave Theory. Mid term price is consolidating in a descending wedge/bull pennant. The safe trade is to buy once price breaks the top of the channel. An aggressive option is to buy when price touches the bottom of the channel. If I buy prior to earnings I will probably trim half my position the day before ER then play the run up to the PDUFA review late November. ***This is not investing advice. I am not an investing professional. Do not invest what you cannot afford to lose. All investors should seek guidance from licensed financial advisers and not random people on the internet.***
LLong
by ruud_one
Basilea Pharmaceutica AG - possible trend changeHello TA family, It looks like the ABC correction is coming to an end. The Price has dropped below FIB 0.78 to shake out the weak hands. Bullish Scenario: The indicators are suggesting bullish momentum, and we have a huge divergence on RSI (daily timeframe) and CCI (daily and weekly timeframe). The bulls have pushed the price above EMA 21 (daily), the next step is to find support above FIB 0.78. I'll ladder in with each confirmation(see the buy boxes). Bearish Scenario: If the price pulls back and drops below the recent low, with the next 2 support lines around 42 and 40, I don't expect any lower price action. In that price area, I'll take the risk and be a buyer, knowing all time high price was 140.
SIX:BSLNLong
by Verethragna
ENDP - BREAKOUT PRONE - UPDATEENDP has been consolidating from it's impressive rally in the beginning of the year. ENDP has shown strong support at it's 52 Week high. It hasn't even retraced .236 of the rally. This leads me to believe we are going to have an extended primary Wave 1. How can we discover that wave 1 was extending? Suppose the minor wave 3 travels more than 161.8% of minor wave 1 then we are seeing an extending wave 1. Suppose wave 3 is of normal proportion. Once the minor wave 4 is finished, you should draw a channel where the lower line connects the bottom of minor wave 2 and minor wave 4. The upper parallel line should be made to touch the top of minor wave 3. If the minor wave 5 goes above the top of this channel, then we are seeing the minor wave 5 within wave 1 extending, which means the whole wave 1 is an extending wave. Extended 3rd Wave: WEEKLY: DAILY: 1HR:
ELong
by FibMarketWatch
BLRX - BioLine RX - Promising Biotech with Big upside - LongBLRX BL-8040 Overview BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. Solid Tumors: In January 2016, BioLineRx entered into a collaboration with MSD, known as Merck in the U.S. and Canada, in the field of cancer immunotherapy. Based on this collaboration, in September 2016 BioLineRx initiated a Phase 2a study, known as the COMBAT study, focusing on evaluating the safety and efficacy of BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in up to 30 patients with metastatic pancreatic adenocarcinoma. The study is an open-label, multicenter, single-arm trial designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity. Partial results will be presented at the 2018 ASCO Gastrointestinal Cancers Symposium (ASCO GI) in January 2018, with top-line results expected in the second half of 2018. September 2016, BioLineRx entered into a collaboration with Genentech , Inc., a member of the Roche Group , in the framework of which both companies would carry out Phase 1b/2 studies investigating BL-8040 in combination with atezolizumab (TECENTRIQ®), Genentech’s anti-PDL1 cancer immunotherapy, in various solid tumors and hematologic malignancies. Genentech commenced a Phase 1b/2 study for the treatment of pancreatic cancer in July 2017, as well as a Phase 1b/2 study in gastric cancer in October 2017. Genentech expects to commence an additional Phase 1b/2 study in lung cancer by early 2018. In September 2017, BioLineRx initiated a Phase 1b/2 study under this collaboration in acute myeloid leukemia (AML). These studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters. n March 2015, BioLineRx reported successful top-line safety and efficacy results from a Phase 1 safety and efficacy trial for the use of BL-8040 as a novel stem-cell mobilization treatment for allogeneic bone marrow transplantation at Hadassah Medical Center in Jerusalem. In March 2016, BioLineRx initiated a Phase 2 trial for BL-8040 for allogeneic stem-cell transplantation, conducted in collaboration with the Washington University School of Medicine, Division of Oncology and Hematology. Initial results of this study announced in March 2017 show that a single injection of BL-8040 mobilized sufficient amounts of cells required for transplantation at a level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care. Topline results of this study are now expected in mid-2018, as a result of certain delays in study recruitment in connection with the addition of two sites to the study and the regulatory filings associated therewith. In August 2017, following a successful meeting with the FDA , BioLineRx announced the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells, or HSCs, for autologous transplantation in patients with multiple myeloma. The trial is expected to commence by the end of 2017. In November 2017, BioLineRx disclosed preclinical data supporting BL-8040 as robust mobilizer of hematopoietic stem cells, or HSCs, associated with long-term engraftment. The data will be presented as an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition in Atlanta, GA, taking place in December 2017. Pre-Clinical Data In vitro and in vivo data show that BL-8040 binds to CXCR4 at the low nanomolar range (1-10nM) and occupies it for prolonged periods of time (>24h). Characterization of the CXCR4 antagonism action of BL-8040 in comparison to other CXCR4 antagonists revealed that, unlike other compounds from the same class, BL-8040 acts as an antagonist as well as an inverse agonist. This activity leads to decreased autonomous signaling of CXCR4 and suggests activity against constitutively active variants. BL-8040 inhibits the growth of various tumor types including multiple myeloma, non-Hodgkin’s lymphoma, leukemia, non-small cell lung carcinoma, neuroblastoma and melanoma. BL-8040 significantly and preferentially stimulated apoptotic cell death of malignant cells (multiple myeloma, non-Hodgkin’s lymphoma and leukemias). Significant synergistic and/or additive tumor cell killing activity has been observed in-vitro and in-vivo when tumor cells were treated with BL-8040 together with Rituximab, Bortezomib, Imatinib, Cytarbine, BCL-2 inhibitor ABT-199 and the FLT-3 inhibitor AC-220 (in NHL, MM, CML, AML, and AML-FLT3-ITD models, respectively). BL-8040 also mobilizes cancer cells as well as neutrophils and progenitor cells from the bone marrow to the peripheral blood. The U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of AML as well as for stem cell mobilization BL-8040 is being developed by BioLineRx under a worldwide, exclusive license from Biokine Therapeutics. 1. Conclusion: The current data demonstrate that BL-8040 induces mobilization of AML blasts from the BM and has sustained receptor occupancy. In addition, a direct effect on AML blast viability has been observed in samples obtained during BL-8040 monotherapy. Importantly, the data suggest a differential effect of BL-8040 monotherapy on AML blasts vs. normal progenitors. BL-8040 was found to be safe and well tolerated at all doses tested to date. The updated results of the dose escalation phase of this ongoing study will be presented. Source: www.bloodjournal.org 2. The FDA approved the first immunotherapy drug recently, but the field dates back to 1891, when William Coley, a physician and cancer researcher, observed that some cancer patients infected by Streptococcus bacteria experienced a dramatic and spontaneous improvement. He began injecting the bacteria into his patients, with mixed results. The treatment was nearly abandoned amid skepticism from Coley’s peers and the advent of radiotherapy and improved surgical techniques. Today, however, new avenues of immunotherapy research are underway, and the field is considered among the most promising new approaches to cancer treatment, according to Jill O’Donnell-Tormey, CEO and director of scientific affairs at CRI. Source: www.jta.org 3. "activated with human interleukin 2, or activated against patients own tumor cells in the laboratory, when such are available – have been extremely successful in killing every last cancer cell in the patients. The theory is the same, in that the cells are trained to act as honing devices." “It’s fantastic because they all were expected to have been dead long ago,” Slavin told ISRAEL21c. “When the laboratory-treated and separated NK cells are infused into a patient, they go immediately to work because they were already trained in the laboratory to become professional killer cells capable of recognizing and destroying foreign cells.” "The new procedure has little or no side effects, is done during fifteen-minute outpatient intravenous infusion and has already showed promising results in high risk patients with metastatic or resistant cancer." "In order for the procedure to be government-approved, a much larger number of patients must successfully undergo treatment." "The reason I am optimistic is because we use mother nature’s tool – immune-system-cells to fight off disease. Normally too, it is the immune system that can recognize cancer cells as undesirable, and under normal circumstances, it will go on an attack until the single abnormal cell, which can grow to a bitter enemy, is gone. In patients with cancer, the patient’s own immune system failed to recognize the enemy and this is why we use the immune system cells from another individual that can easily recognize and destroy such tumor cells escaping the attention of patient’s immune system,” said Slavin." Summary Source: seekingalpha.com In two January ASCO presentations, BL-8040 showed robust infiltration of anti-tumor T-cells into liver metastases in pancreatic cancer and primes the tumor micro-environment to enhance the effectiveness of immunotherapy agents. New oncology asset AGI-134 induced complete tumor regression in 50% and 67% of two mice melanoma preclinical studies. The company plans to start Phase 1/2a clinical trials in 1H 2018. BiolineRx is funded to 2020 with $55M in cash, no debt. However cash balance might be higher since it's likely company was selling against a $30M ATM since November. The company has plans to deliver up to a dozen high-potential catalysts in 2018 following a busy January (4 conferences, and 4 clinical data). Institutional ownership has increased from 20% to almost 60% in a year. Five analysts have a consensus Buy rating with $3.5/share price target. Chart Screenshots: screenshots.firefox.com screenshots.firefox.com screenshots.firefox.com Will update. -AB
NASDAQ:BLRXLong
by FibMarketWatch
ENDP - SHORT-TERM SHORT & LONG-TERM BUY - Endo Pharma ENDP Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. The Crash: Revenue Is In Free Fall Endo Pharmaceuticals: The Free Fall Continues Mar. 26, 2018 Summary Revenue from ENDP's core Generics business is in decline and other business segments appear in disarray. Its $8B debt load is at 7.5x run-rate EBITDA. If operating income continues to slide, it could hurt ENDP's ability to service its debt. ENDP ENDP trades at 9x EBITDA, but it is uncertain if potential legal exposures pursuant to opioids are priced in. Sell ENDP. This idea was discussed in more depth with members of my private investing community, Shocking The Street. There is a war being fought over drug prices. Lawmakers have hit back at price gougers and opioid manufacturers, and Endo Pharmaceuticals (ENDP) is in the middle of it. A few months ago, I thought Endo was at an inflection point and there was a good probability it could turn things around. However, its slide continues. What: The bottom dropped out from under shares of Endo International plc (NASDAQ:ENDP), the specialty pharma famous for selling "uncrushable" opioids and agreeing to enormous legal settlements. After management revealed disturbing revisions of its 2016 full-year estimates, the stock plummeted 41.4% last month, according to data from S&P Global Market Intelligence. Logical? Sold because they sell opiates? Are opiated still needed/critical to US Healthcare? NO! BIG Consolidation period: 4 Years (2014-2018) The First CYCLE WAVE Completed. Now, in the middle of the SECOND WAVE (Correction) Key Levels for Retrace: 1, 1.382, & 1.618 Look for retrace back to around $13.00 ENDP screenshots.firefox.com screenshots.firefox.com screenshots.firefox.com Most Recent News: Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law. Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law. Analysts at RBC Capital upgraded Endo International PLC (NASDAQ:ENDP) from Sector Perform to Outperform. Endo shares rose 2.56 percent to $16.05 in pre-market trading. Will update. -Stay humble America, -AB
ELong
by FibMarketWatch